Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trialCOVID-19 관련 중등도에서 중증 급성 호흡 곤란 증후군(ICAR) 환자의 정맥 면역글로불린: 다기관, 이중 맹검, 위약 대조, 3상 시험Clinical Trial Published on 2022-02-012022-09-12 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 acute respiratory distress Administered administration adverse event adverse events ARDS Clinique complication of COVID-19 COVID-19 disease stage distress double-blind eligible event for inclusion France Frequency high mortality Immunoglobulin IMPROVE improve clinical outcome Inclusion intention-to-treat analysis intention-to-treat principle Intravenous immunoglobulin Invasive mechanical ventilation Lung injury morbidity multicentre no statistical difference not significant outcome Patient patients patients with COVID-19 PCR phase 3 trial Placebo placebo-controlled placebo-controlled trial Primary outcome Randomly randomly assigned patient receive receiving reducing Registered risk Serious Adverse Events Sodium chloride stratified syndrome the median the placebo group Treatment Trial trials Volume was done web-based system women [DOI] 10.1016/S2213-2600(21)00440-9 PMC 바로가기 [Article Type] Clinical Trial
Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized TrialmRNA-1273 백신 2회 및 3회 접종 후 이식 수혜자의 SARS-CoV-2 변이체 중화: 무작위 시험의 2차 분석Randomized Controlled Trial Published on 2022-02-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] Alpha Alpha variant Analysis analyzed Antibody Response assays Beta Beta variant Controlled trial COVID-19 delta variant Delta variants dose doses double-blind increase lentivirus mRNA mRNA vaccine mRNA-1273 mRNA-1273 vaccine neutralization neutralizing antibody Neutralizing antibody response neutralizing antibody responses Organ transplant Patient percentage points Placebo placebo group positive proportion Pseudovirus neutralization assay Randomized recipient recipients SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants secondary sera the placebo group Transplant vaccine doses vaccine immunogenicity variant variants Virus neutralization viruses wild-type virus [DOI] 10.7326/M21-3480 PMC 바로가기 [Article Type] Randomized Controlled Trial
Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials A Systematic Review and Meta-analysisCOVID-19 백신 시험의 위약군에서 이상 반응 빈도 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-01-182022-09-10 Journal: JAMA Network Open [Category] SARS, 치료제, [키워드] 95% CI 95% CIs accounted Adverse adverse event adverse events AEs analyzed Arm ARMS article clinical trial clinical trials Controlled controlled trials COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccine trial COVID-19 vaccine trials COVID-19 vaccines data extraction database dose drug trials eligibility evaluate event Evidence extraction fatigue finding first dose frequencies Frequency groups headache Importance independent injection investigated item Local measure meta-analyses Meta-analysis objective Odds ratio Older participant performed Placebo placebo group placebo recipient placebo recipients placebo treatment Point Primary outcome Primary outcomes PRISMA proportion proportions provided Public Random-effects models Randomized reason reason for recipient recipients Relevance reported Reporting response Result review searched second dose selected Selection significantly more Source standardized mean difference synthesis systematic review systematic reviews systemic AE systemic AEs tested the placebo group the vaccine Trial trial participants vaccination Vaccine vaccine group vaccine trial [DOI] 10.1001/jamanetworkopen.2021.43955 PMC 바로가기 [Article Type] Meta-Analysis
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trialRandomized Controlled Trial Published on 2022-01-062022-10-05 Journal: The European Respiratory Journal [Category] Fulltext, SARS, 임상, [키워드] acute respiratory syndrome airway antibiotic antiviral properties Azithromycin cause Combination control group coronavirus coronavirus disease COVID-19 criteria days alive death discharged double-blind double-blinded enrolment hospital hospitalisation hospitalised hospitalised patient Hydroxychloroquine immunomodulatory effects IMPROVE in vitro induce intensive care interim analysis interquartile range Intervention intervention group median monitoring board multicentre nine occurred outcome Patient patients patients receiving placebo patients with COVID-19 Placebo placebo-controlled trial positive Primary outcome randomisation randomised recruited reverse transcription PCR SARS-CoV-2 survival the placebo group Trial [DOI] 10.1183/13993003.00752-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial
Promising Effects of 3-Month Period of Quercetin Phytosome ® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot StudyArticle Published on 2022-01-042022-10-29 Journal: International Review of Cell and Molecular Biology [Category] COVID-19, [키워드] age chronic disease control group COVID COVID-19 COVID-19 infection diagnostic test Effect enrolled evaluate females Gender group groups males Period Placebo prevention Prophylaxis quercetin required risk of infection SARS-CoV-2 shown significant difference smoking subject survival symptomatic the placebo group was recorded [DOI] 10.3390/life12010066 PMC 바로가기 [Article Type] Article
Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trialRandomized Controlled Trial Published on 2022-01-032022-10-04 Journal: Critical Care [Category] 임상, [키워드] 1:1 abnormality Admission Affect blood gas analysis characterized Computed tomography conducted control group COVID-19 COVID-19 patient Efficacy eligible adult enrolled evaluate Follow-up group hospital Hospital stay Hospitalized hypoperfusion ICU IMV Infection Inpatient intensive care unit intention-to-treat basis intervention group Invasive mechanical ventilation IQR Length of stay lung lung parenchyma mechanical ventilation median median age mortality rates non-invasive ventilation outcome Oxygenation PaO parameter parameters participant Patient patients with COVID-19 performed Placebo placebo-controlled trial Randomized randomized trial Registration Regulation repeated-measures ANOVA required Result SARS-CoV-2 secondary Seven significant difference significantly shorter Sildenafil statistically significant difference Subtraction CT angiography supplementary material the placebo group therapeutic treating COVID-19 Treatment Ventilation–perfusion ratio ventilatory support was performed were excluded [DOI] 10.1186/s13054-021-03885-y PMC 바로가기 [Article Type] Randomized Controlled Trial
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trialRandomized Controlled Trial Published on 2022-01-012022-10-05 Journal: The Lancet. Global health [Category] Fulltext, SARS, 신약개발, 임상, 치료법, [키워드] 1:1 95% CI Abstract Adaptive platform trial adverse event age Analysis Arm assigned average Bayesian Bayesian credible interval BCI Brazil Care clinical trial composite endpoint COVID-19 COVID-19 emergency death defined diagnosed early treatment Effect Efficacy eligible patient events Evidence female finding foundation groups hospital hospitalisation hospitalisations indicate initiated intention to treat intention-to-treat analysis Intervention material modified intention-to-treat no significant difference Odds ratio Outpatient participant Patient per-protocol analysis per-protocol population Placebo placebo-controlled platform positive potential participant Primary outcome Probability progression proportion protocol randomisation randomised Randomly receiving recent reduced Registered reported risk risk factor SARS-CoV-2 screened severe disease symptomatic symptomatic patient the placebo group therapeutic threshold transfer transferred translation Treatment treatment allocation treatment group Trial with COVID-19 [DOI] 10.1016/S2214-109X(21)00448-4 PMC 바로가기 [Article Type] Randomized Controlled Trial
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trialClinical Trial Published on 2022-01-012022-10-04 Journal: EBioMedicine [Category] 바이오마커, 임상, 치료법, [키워드] 1-year follow-up results administration adverse event analyzed antibody benefit Biomarkers Cell China clinical trial cohort study consequence COVID-19 COVID-19 patients double-blind Effectiveness enrolled evaluate Follow-up follow-up time foundation group High-resolution CT Human in both group incidence Innovation interval Lung function lung lesion Major median mesenchymal stem cell Mesenchymal stem cells treatment MSC natural Other outcome outcomes Patient phase 2 trial Placebo placebo-controlled trial plasma positive primary endpoint Program proportion Randomized RCT RCT. recorded recruited reduced Registered reported Science severe COVID-19 stem cell Symptom technology the placebo group Treatment treatment for COVID-19 Trial tumor marker two groups UC-MSC umbilical Volume walking distance [DOI] 10.1016/j.ebiom.2021.103789 PMC 바로가기 [Article Type] Clinical Trial
Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV TrialEndocrinology/Diabetes/Metabolism Published on 2021-12-252022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 1:1 95% CI 95% confidence interval ACE2 addition all-cause mortality androgen Androgen receptor angiotensin-converting enzyme 2 antiandrogens Arm ARMS baseline Brazil clinical clinical trial COVID COVID-19 Day demonstrated discharge Drug efficacy effective Efficacy evaluate expression female Final highest hospital Hospital stay Hospitalization hospitalized COVID-19 patient hospitalized COVID-19 patients improvement Inflammatory response interquartile range IQR joint material median mortality rate mortality rates North outcome outcomes oxygen pandemic performed Placebo placebo group preliminary report Prevent proxalutamide randomization randomized clinical trial RCT RCTs reduced reduction in Region Regulation Result risk ratio SARS-CoV-2 score Sepsis South statistical analysis statistically statistically significant stratified by sex study population subject the placebo group TMPRSS2 transmembrane protease serine 2 Trial usual care was performed WHO [DOI] 10.7759/cureus.20691 PMC 바로가기 [Article Type] Endocrinology/Diabetes/Metabolism
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients외래 환자에서 중증 코로나19로의 진행을 예방하기 위한 조기 렘데시비르Randomized Controlled Trial Published on 2021-12-222022-09-25 Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 신약개발, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval Adverse adverse event age assigned Clinical outcome condition conducted coronavirus disease Course death Diabetes Mellitus died Disease progression dose double-blind efficacy end point end point EudraCT event hazard ratio high risk Hispanic Hospitalization hypertension IMPROVE Intravenous remdesivir Latinx lower risk Medical conditions obesity occurred Outpatient Patient patients hospitalized Placebo placebo-controlled trial Prevent progression randomization Randomized Randomly receive Remdesivir Result risk factor safety profile symptom onset symptomatic the patient the placebo group women [DOI] 10.1056/NEJMoa2116846 PMC 바로가기 [Article Type] Randomized Controlled Trial